House passes sweeping Pelosi bill to lower drug prices

The House on Thursday passed a sweeping bill aimed at lowering prescription drug prices, a step toward a long-held Democratic goal that was met with sharp Republican resistance.

The bill passed on a largely party-line vote of 230-192. The measure, which would allow the government to negotiate lower prices for prescription drugs, is one of House Democrats’ top priorities and is expected to be touted by vulnerable Democrats up for reelection next year.

The party is also looking to show that it is focused on kitchen table issues like lowering drug costs even as lawmakers prepare for an impeachment vote against President TrumpDonald John TrumpBiden says his faith is 'bedrock foundation of my life' after Trump claim Coronavirus talks on life support as parties dig in, pass blame Ohio governor tests negative in second coronavirus test MORE.

ADVERTISEMENT

“What I hear most often is not impeachment, it's not what's on the front page of The Washington Post, it's ‘What are you going to do about the cost of our prescription drugs?’ ” said Rep. Kim SchrierKimberly (Kim) Merle SchrierWashington Rep. Kim Schrier wins primary US ill-prepared for coronavirus-fueled mental health crisis Gun control group rolls out House endorsements MORE (D-Wash.), one of several freshmen facing competitive reelection races who showcased the bill on the Capitol steps Thursday. “And this bill is an answer to my constituents.”

Two Republicans voted in favor of the bill: Reps. Brian FitzpatrickBrian K. Fitzpatrick2020 Global Tiger Day comes with good news, but Congress still has work to do How Congress is preventing a Medicare bankruptcy during COVID-19 Overnight Energy: House passes major conservation bill, sending to Trump | EPA finalizes rule to speed up review of industry permits MORE (Pa.) and Jaime Herrera BeutlerJaime Lynn Herrera BeutlerGOP Rep. Jaime Herrera Beutler advances in Washington primary House votes to curtail Insurrection Act powers Cook shifts 20 House districts toward Democrats MORE (Wash.), both moderates who face competitive reelection races next year. No Democrats voted against the bill.

The measure drew support from progressives following months of negotiations that cleared the way for it to pass this week. The bill is almost certain to die in the GOP-led Senate, though, given that Senate Majority Leader Mitch McConnellAddison (Mitch) Mitchell McConnellCoronavirus talks on life support as parties dig in, pass blame Jobs report poised to light fire under COVID-19 talks Overnight Health Care: Ohio governor tests positive for COVID-19 ahead of Trump's visit | US shows signs of coronavirus peak, but difficult days lie ahead | Trump: COVID-19 vaccine may be ready 'right around' Election Day MORE (R-Ky.) has called it “socialist” and vowed to block it. Republicans warn the measure would hinder the development of new treatments and impose “price controls.”

It is possible that smaller measures to lower drug prices could become law, given a bipartisan push to do something on the topic, but a path forward remains unclear amid division and multiple competing proposals.

Pelosi had tried for months to win Trump’s support for the bill, given that he broke from Republican orthodoxy and supported government negotiation on drug prices during his 2016 campaign.

After months of talks between Pelosi’s staff and the White House, though, the administration came out against the measure, leading Democrats to say Trump is breaking his promise to support negotiation for lower prices.

ADVERTISEMENT

“It’s exactly what President Trump promised on the campaign trail,” said Rep. Andy LevinAndrew (Andy) LevinOVERNIGHT ENERGY: 20 states sue over Trump rule limiting states from blocking pipeline projects | House Democrats add 'forever chemicals' provisions to defense bill after spiking big amendment | Lawmakers seek extension for tribes to spend stimulus money House Democrats add some 'forever chemicals' provisions to defense bill after spiking major amendment US, Mexico set for new post-NAFTA trade era MORE (D-Mich.).

Trump is instead supporting a more modest bipartisan bill in the Senate to lower drug prices, legislation that does not include a provision to negotiate prices.

The House bill, known as the Elijah E. Cummings Lower Drug Costs Now Act, is named for the late Democratic lawmaker who was a champion of lowering drug prices.

The legislation would allow the secretary of Health and Human Services to negotiate lower prices for a minimum of 50 drugs per year, up to a maximum of 250 drugs. The prices for those drugs would also be capped at 120 percent of the prices in certain other wealthy countries. The government would then negotiate to bring prices down even further below that cap.

The lower prices would apply to people on private insurance in addition to those on Medicare.

If a drug company refused to negotiate, the company would be hit with a tax up to 95 percent of the revenue for the drug.

That steep penalty has led Republicans to argue the bill is not really “negotiation” as Democrats claim, but is effectively just mandating the price that drug companies must sell their products at.

The White House said the bill would impose “price controls” in its message threatening to veto the measure.

Progressive House Democrats had resisted the bill from the other direction, arguing that the measure did not go far enough. Reps. Pramila JayapalPramila JayapalSanders offers bill to tax billionaires' wealth gains during pandemic Matt Stoller: Big tech House grilling the most important hearing on corporate power since the 1930s Hillicon Valley: House panel grills tech CEOs during much anticipated antitrust hearing | TikTok to make code public as it pushes back against 'misinformation' | House Intel panel expands access to foreign disinformation evidence MORE (D-Wash.) and Mark PocanMark William PocanProgressive Caucus co-chair: Reported oversight change in intelligence office 'seems a bit...fascist' House approves amendments to rein in federal forces in cities House Democrats backtrack, will pull Homeland Security bill MORE (D-Wis.), along with Rep. Lloyd DoggettLloyd Alton DoggettOvernight Health Care: Fauci says family has faced threats | Moderna to charge to a dose for its vaccine | NYC adding checkpoints to enforce quarantine GOP plan would boost deduction for business meals Gilead sets price for five-day coronavirus treatment at ,120 MORE (D-Texas), spent months pushing Pelosi to make the bill tougher.

In recent days they threatened to try to block a vote on the bill unless changes were made, but struck a deal with Pelosi after a meeting in the Speaker’s office Tuesday, clearing the way for the bill to pass with minimal drama. One of the changes increased the minimum number of drugs to be negotiated from 35 to 50.

The Congressional Budget Office (CBO) found the bill would lower prices by about 50 percent for drugs subject to negotiation and save $456 billion over 10 years. The bill then invests those savings in expanding Medicare benefits to include hearing, dental and vision care.

On the other hand, the CBO also found the bill would result in eight fewer drugs being developed over a decade, out of about 300 usually introduced in that time period. 

ADVERTISEMENT

House Republicans put forward a competing proposal that also received a vote Thursday. Their bill is much smaller in scale. Republicans touted it as leading to lower prices without imposing “price controls” or threatening the development of new drugs. 

House Minority Leader Kevin McCarthyKevin Owen McCarthyJudge throws out House GOP lawsuit over proxy voting Republicans fear disaster in November Gaetz set to endorse primary opponent of fellow Florida GOP lawmaker MORE (R-Calif.) called the Democratic bill a move to “appease the progressive base and have a partisan bill that denies us more cures,” while calling the GOP alternative a “practical solution” that would still allow new cures to come to market.

Democrats say polling shows the public is behind their bill. The progressive group Data for Progress on Thursday released polling testing different messages about the bill and finding strong support. Opposition never rose above 40 percent even when voters were presented with only negative messages about the bill. 

Pelosi said on the House floor on Thursday that she did not know why the White House stopped working with her on the drug pricing bill.

“We were working with the interests of the White House, the administration, on all of this,” she said. “I don't where it happened, but somewhere along the way, negotiation and the rest fell by the by. And what that could be attributed to, I don't know what.”

Updated: 2:30 p.m.